immatics
appoints
biotech
executive
eliot
forster
board
directors
tuebingen
germany
houston
texas
september
immatics
nasdaq
imtx
immatics
biopharmaceutical
company
active
discovery
development
cell
redirecting
cancer
immunotherapies
announced
today
appointment
eliot
forster
phd
board
directors
forster
currently
serves
chief
executive
officer
ceo
bispecific
antibody
developer
therapeutics
chairman
avacta
plc
brings
immatics
extensive
experience
including
leadership
trailblazing
biopharmaceutical
companies
field
others
strengthen
immatics
board
company
develops
pipeline
cell
receptor
tcr
therapeutics
peter
chambr√©
chairman
immatics
board
directors
commented
able
attract
eliot
board
testament
transformational
science
corporate
culture
immatics
established
momentum
company
gained
towards
bringing
power
cells
cancer
patients
delighted
eliot
join
board
look
forward
counsel
continue
implementing
strategies
achieve
clinical
milestones
immatics
next
development
eliot
forster
added
time
cancer
immunotherapies
hold
great
promise
future
immatics
developed
powerful
approach
discover
address
novel
cancer
targets
previously
inaccessible
current
therapies
company
broad
pipeline
includes
tcr
product
candidates
target
tumor
cells
also
microenvironment
potential
transform
landscape
treatments
thrilled
joining
board
immatics
company
watched
admired
long
time
looking
forward
working
board
well
harpreet
team
develop
company
cell
technology
transform
lives
patients
eliot
forster
joined
therapeutics
leadership
significantly
increased
portfolio
products
list
company
nasdaq
recently
announced
combination
spring
bank
pharmaceuticals
joining
eliot
forster
served
ceo
immunocore
tenure
responsible
raising
considerable
capital
steering
company
strategy
infectious
diseases
autoimmune
diseases
well
establishing
clinical
collaborations
global
pharmaceutical
companies
prior
ceo
creabilis
therapeutics
solace
pharmaceuticals
forster
previous
positions
include
head
development
operations
eu
asia
pfizer
founding
chairman
medcity
forster
holds
phd
neurophysiology
liverpool
university
mba
henley
management
college
notes
editors
immatics
immatics
combines
discovery
true
targets
cancer
immunotherapies
development
right
cell
receptors
goal
enabling
robust
specific
cell
response
targets
deep
foundation
pipeline
adoptive
cell
therapies
tcr
bispecifics
well
partnerships
global
leaders
pharmaceutical
industry
committed
delivering
power
cells
unlocking
new
avenues
patients
fight
cancer
regular
updates
immatics
visit
also
follow
us
twitter
linkedin
statements
certain
statements
press
release
may
considered
statements
statements
generally
relate
future
events
immatics
future
financial
operating
performance
example
statements
concerning
timing
product
candidates
immatics
focus
partnerships
advance
strategy
statements
cases
identify
statements
terminology
may
expect
intend
estimate
anticipate
believe
predict
potential
continue
negatives
terms
variations
similar
terminology
statements
subject
risks
uncertainties
factors
could
cause
actual
results
differ
materially
expressed
implied
forward
looking
statements
statements
based
upon
estimates
assumptions
considered
reasonable
immatics
management
inherently
uncertain
new
risks
uncertainties
may
emerge
time
time
possible
predict
risks
uncertainties
factors
may
cause
actual
results
differ
materially
current
expectations
include
limited
various
factors
beyond
management
control
including
general
economic
conditions
risks
uncertainties
factors
set
forth
filings
securities
exchange
commission
sec
nothing
presentation
regarded
representation
person
statements
set
forth
herein
achieved
contemplated
results
statements
achieved
place
undue
reliance
statements
speak
date
made
immatics
undertakes
duty
update
statements
information
please
contact
media
enquiries
investor
relations
contact
gretchen
schweitzer
jacob
verghese
phd
john
graziano
trophic
communications
solebury
trout
phone
phone
immatics
jgraziano
immatics
anja
heuer
jordan
silverstein
corporate
communications
head
strategy
phone
phone
media
investorrelations
attachments
